Heart; Surgery, Heart, Functional Disturbance as Result
Conditions
Keywords
syndecan-1, endothelial glycocalyx, On-pump heart surgery
Brief summary
Evaluation of endothelial glycocalyx damage in on-pump conventional coronary artery bypass surgery using a syndecan-1 (CD138) blood test. The study will be carried out in two stages. Pilot study for testing and correcting research methodology and the main study.
Detailed description
Study tasks: 1. To evaluate changes of syndecan-1 concentration during surgery and postoperative period. 2. Determine the effect of aortic clamping and on-pump duration on endothelial glycocalyx damage. 3. Assess the risk of early postoperative complications and syndecan-1 plasma concentrations. 4. To evaluate the correlation of inflammatory status with glycocalyx damage. 5. To evaluate glycocalyx damage to patients with diabetes vs non-diabetes. Methods: Patients undergoing cardiopulmonary bypass surgery are being treated at the Heart, Chest and Vascular Surgery Clinic of the Lithuanian University of Health Sciences Hospital in Kaunas Clinics. After receiving patients written consent a syndecan-1 concentration test will be performed upon arrival at the operating room, before cardiopulmonary bypass (CPB), after CPB, upon arrival in the ICU and after 24 hours. All needed data for evaluating patients outcome will be taken from medical documentation during patients stay in hospital.
Interventions
DIAGNOSTIC_TESTSyndecan-1 concentration evaluation
Blood sample will be taken and analysed using ELISA method.
Sponsors
Lithuanian University of Health Sciences
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Elective on-pump coronary artery bypass surgery needed. * Normal heart function at the time of operation. * Patients without infections. * Patients who signed study informed consent form
Exclusion criteria
* Life saving operation. * Renal or hepatic dysfunction. * Off-pump heart operation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes of syndecan-1 concentration during surgery and postoperative period. | 2 years | Concentration of syndecan-1 will be measured by taking patients blood sample before operation, after aortic cannulation, after CPB, when arriving to ICU and 24 hours after operation. Means of concentration changes will be compared to determine which period of operation has the biggest impact to endothelial glycocalyx shedding. |
| The evaluation of aortic clamping and on-pump duration on endothelial glycocalyx damage using syndecan-1 concentration measure. | 2 years | Concentrations of syndecan-1 will be evaluated considering the duration of aortic clamping and CPB. Optimal duration will be searched for minimal impact to endothelial glycocalyx. |
| Assess the risk of early postoperative complications and find possible correlation to syndecan-1 concentration changes. | 2 years | All negative events after operation will be recorded and statistically correlated with syndecan-1 concentration changes. |
| The correlation of inflammatory status with glycocalyx damage. | 2 years | Leucocytosis and C reactive protein levels will be evaluated before, after heart operation and 24 hours later. Data will be compared to syndecan-1 concentration changes. |
| Glycocalyx damage to patients with diabetes vs non-diabetes during heart surgery. | 2 years | Compare glycocalyx damage using syndecan-1 concentration changes to diabetic and non-diabetic patents during heart surgery. |
Countries
Lithuania
Contacts
STUDY_CHAIRTadas Lenkutis, Doc.
Heart centre, Lithuanian University of Health Sciences
PRINCIPAL_INVESTIGATORTadas Cesnaitis, MD
Heart centre, Lithuanian University of Health Sciences
Outcome results
None listed